BEAM vs WSFS Comparison

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

WSFS Financial Corp is a savings and loan holding company. The company operates in three segments: WSFS Bank provides loans and leases and other financial products to commercial and consumer customers. Cash Connect segment provides ATM vault cash, smart safe, and other cash logistics services; and Wealth Management provides a broad array of planning and advisor services, investment management, personal and institutional trust services, and credit and deposit products to individuals, corporate, and institutional clients. Majority revenue is generated from WSFS Bank segment.